XClose

UCL Division of Medicine

Home
Menu

UCL Division of Medicine

Research

The Division undertakes world-leading basic and translational research that impacts upon understanding, diagnosis and treatment of human disease.

Landmark achievements of the Division include Professor Brian Prichard’s seminal discovery that the beta-blocker, propanolol, reduces blood pressure, the development by Prof Jonathan Edwards of B cell depletion therapy (rituximab) to treat rheumatoid arthritis, and the pioneering work of the National Amyloidosis Centre established by Professor Sir Mark Pepys FRS, in non-invasive patient diagnosis and monitoring.

The Division’s research has also had economic impact through the generation of spin-off enterprises attracting major investment, such as Ark Therapeutics Ltd, co-founded by Professor John Martin, and Pentraxin Therapeutics Ltd, co-founded by Professor Sir Mark Pepys FRS. Find out more about our research by going to individual Centre or Institute websites.


Centres and Institutes

Centres and Institutes

View our Centres and Institutes

Core Facilities

Core Facilities

View our Core Facilities

PhD/MD Opportunities

PhD/MD Opportunities

View our PhD/MD Opportunities